Todos Medical aktsepteerib nüüd Tollovidi ostmiseks krüptovaluutat

 Tollovid Daily™ through Coinbase Commerce

Aktsepteeritavate krüptovaluutade hulka kuuluvad Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Cash (BCH) ja Litecoin (LTC).

New York, NY & Tel Aviv, Israel, Sept. 19, 2021 (GLOBE NEWSWIRE) — (via Blockchaini traat) Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and solutions company with comprehensive product offerings, announced that it is now accepting Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Cash (BCH) and Litecoin (LTC) as payment for the Company’s proprietary 3CL protease inhibitor wellness products Tollovid® and Tollovid Daily™. The Company is able to accept these forms of payments through its www.mytollovid.com website when purchasers select Coinbase Commerce as the form of payment at checkout.

“We believe strongly that everyone should take Tollovid to support their immune function during times of significant immune challenge and should be taking Tollovid Daily each and every day in order to maintain consistent, healthy immune function,” said Gerald E. Commissiong, President & CEO of Todos Medical. “The ability to accept widely utilized cryptocurrency is an important step as we broaden our marketing efforts around our novel 3CL protease inhibitor wellness products.”

Tollovid and Tollovid Daily are dietary supplement products that have both received Certificates of Free Sale from the U.S. Food & Drug Administration (FDA), authorizing the marketing and sale of these products in the United States. The FDA has allowed the Company to make two specific claims with regards to each product:

1. Tollovid and Tollovid Daily help to support and maintain healthy immune function; and
2. Tollovid and Tollovid Daily are 3CL protease inhibitors.

Tollovid is targeted to customers that need maximum immune support, whereas Tollovid Daily addresses customers that require or could benefit from daily immune support. Both Tollovid and Tollovid Daily can be purchased via subscription and now, utilizing cryptocurrency

Lisateabe saamiseks külastage palun www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.

Teave Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 20201, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.

Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States. The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.

Lisateabe saamiseks külastage palun https://www.todosmedical.com

Tulevikku suunatud avaldused

Teatud selles pressiteates sisalduvad avaldused võivad olla tulevikku suunatud avaldused. Näiteks kasutatakse tulevikku suunatud avaldusi meie eeldatavate kliiniliste arendusprogrammide ja kliiniliste uuringute arutamisel. Need tulevikku suunatud avaldused põhinevad ainult juhtkonna praegustel ootustel ning on seotud oluliste riskide ja ebakindlusega, mille tõttu võivad tegelikud tulemused oluliselt erineda tulevikku suunatud avaldustes kirjeldatutest, sealhulgas edusammudega seotud riskid ja ebakindlus, kliiniliste uuringute ja tootearendusprogrammide ajastus, maksumus ja tulemused; raskused või viivitused tootekandidaatide regulatiivse heakskiidu või patendikaitse saamisel; teiste biotehnoloogiaettevõtete konkurents; ja meie võime saada täiendavaid rahalisi vahendeid, mis on vajalikud meie uurimis-, arendus- ja turustamistegevuste läbiviimiseks. Lisaks võivad muu hulgas järgmised tegurid põhjustada tegelike tulemuste olulist erinevust tulevikku suunatud avaldustes kirjeldatutest: tehnoloogia ja turunõuete muutused; viivitused või takistused meie kliiniliste uuringute käivitamisel; muudatused seadusandluses; võimetus õigeaegselt välja töötada ja kasutusele võtta uusi tehnoloogiaid, tooteid ja rakendusi; meie tehnoloogia valideerimise puudumine edusammude edenedes ja teadusringkondade poolt meie meetodite mitteaktsepteerimine; võimetus säilitada või meelitada võtmetöötajaid, kelle teadmised on meie toodete arendamisel hädavajalikud; ettenägematud teaduslikud raskused, mis võivad meie protsessi käigus tekkida; oodatust suurem lõpptoote maksumus; turuosa kaotus ja konkurentsist tulenev surve hinnakujundusele; ja laboratoorsed tulemused, mis ei anna tegelikes tingimustes võrdselt häid tulemusi, mis kõik võivad põhjustada tegelikke tulemusi või tulemuslikkust oluliselt erineda sellistest tulevikku suunatud avaldustest. Kui seaduses ei ole sätestatud teisiti, ei võta Todos Medical kohustust avalikult avaldada nende tulevikku suunatud avalduste parandusi, et kajastada sündmusi või asjaolusid pärast käesoleva kuupäeva kuupäeva või kajastada ettenägematuid sündmusi. Todos Medicali mõjutavate riskide ja ebakindluse üksikasjalikuma kirjelduse leiate selle aruannetest, mis esitatakse aeg -ajalt USA väärtpaberite ja börsikomisjonile.

Richard Galterio
Todos Medical, Ltd
732-642-7770
rich.g@todosmedical.com

Source: https://e-cryptonews.com/todos-medical-now-accepting-cryptocurrency-for-the-purchase-of-tollovid/